The opinion of the court was delivered by: Rufe, J.
Before the Court is the Motion of Defendants/Third-Party Plaintiffs to Remand this action to the Court of Common Pleas of Philadelphia County. The Motion is opposed by the Third-Party/Counterclaim Defendants, who fall into two groups: (1) King Pharmaceuticals, Inc. and King Pharmaceuticals Research and Development, Inc. (the "King Defendants"); and (2) Mutual Pharmaceutical Company, Inc. ("Mutual"), United Research Laboratories, Inc., Richard Roberts, Pharmaceutical IP Holdings, Inc., and Pharmaceutical Holdings Company, Inc. (the "Mutual Defendants").
On or about May 5, 2011, Mutual Pharmaceutical Company, Inc. and
United Research Laboratories, Inc. (the "Original Plaintiffs") filed a
complaint in the Philadelphia Court of Common Pleas against Dr.
Spireas, Dr. Bolton, and Hygrosol Pharmaceutical Corp. ("Hygrosol")
(collectively, the "Original Defendants"), *fn1
seeking a declaratory judgment and damages based on
breach of contract, fraudulent misrepresentation and unjust enrichment
related to a 1998 License Agreement regarding certain "liquisolid
technology" patents. *fn2 On or about January
6, 2012, Spireas and Hygrosol (the "Third-Party Plaintiffs") filed an
answer and asserted counterclaims for breach of the License Agreement,
disclosure of confidential information, conversion, and fraud,
alleging that the Original Plaintiffs failed to pay a percentage of
the profits owed under the License Agreement for Mutual's use of
products developed using Original Defendants' patents and technology,
including formulations for metaxalone products sub-licensed by Mutual
to the King Defendants. *fn3
Spireas and Hygrosol also filed a "third-party complaint" against the Mutual and King Defendants asserting, inter alia , state claims for restraint of trade under Pennsylvania and California law, civil conspiracy, fraud and breach of contract, and federal claims for violations of the Racketeer Influenced and Corrupt Organizations Act ("RICO") related to the Third-Party Defendants' use of all metaxalone products developed by Dr. Spireas. *fn4 Third-Party Plaintiffs allege that Third-Party Defendants' agreements and illegal actions relate to both (a) formulations for at least two "more bioavailable metaxalone-based muscle relaxant drug" formulations developed pursuant to the 1998 License Agreement, and (b) two generic formulations for the King Defendants' branded metaxalone-based product Skelaxin (one which could be developed under the 1998 License Agreement with Hygrosol, and one which was subject to a 1999 Development Agreement between certain Mutual Defendants and SigmaPharm, Inc., Dr. Spireas's wholly owned company). *fn5
All Third-Party/Counterclaim Defendants removed the action to this Court based on federal-question jurisdiction over the RICO claims in the Third-Party Complaint, *fn6 and Third-Party Plaintiffs seek to remand. *fn7
The Court of Appeals for the Third Circuit has not ruled directly on whether a third-party defendant may properly remove an action under 28 U.S.C. § 1441. *fn8 However, it has been the view of the majority of federal courts that neither counterclaim defendants nor third-party defendants may remove a civil action from state court to federal court pursuant to § 1441, because such parties are not "defendants" within the meaning of § 1441(a), which states in pertinent part that "any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed by the defendant or the defendants . . . ." *fn9
In so holding, these courts have followed the "long-accepted
practice of deferring to the Plaintiff's choice of forum by treating
the Plaintiff as master of his own complaint," *fn10
as well as the principle that "removal statutes are to be
strictly construed against removal and all doubts . . . resolved in
favor of remand." *fn11 Some courts have also
concluded that the accepted meaning of
the term "joined" does not authorize removal by a third-party
defendant pursuant to § 1441(c), because a third-party claim is
typically "antagonistic to" rather than "joined with" a plaintiff's
original claims. *fn12 The Court finds the
majority view persuasive in this case, especially as the third-party
claims appear to be intertwined with the original cause of
Third-Party Defendants argue that amendments to 28 U.S.C. § 1441(c) effective January 6, 2012 allow the removal by any party of any action containing federal claims. The Court does not agree. The prior language of § 1441(c) read: (c) Whenever a separate and independent claim or cause of action within the jurisdiction conferred by section 1331 of this title is joined with one or more otherwise non-removable claims or causes of action, the entire case may be removed and the district court may determine all issues therein, or, in its discretion, may remand all matters in which State law predominates.
As amended, the subsection reads:
(c) Joinder of Federal law claims and State law claims.--
(1) If a civil action includes --
(A) a claim arising under the Constitution, laws, or treaties of the United States (within the meaning of ...